Microdosing means small oral amounts of the main intoxicating compound in cannabis, below noticeable intoxication, aimed at health and longevity. Human evidence for a longevity benefit is absent; appeal rests largely on studies in old mice. Better-supported benefits, such as nausea and appetite-loss relief, come from patient groups, mostly at higher doses. Dose-related dizziness, drowsiness, anxiety, and impaired driving are the most consistently documented downsides; microdose risk is unmeasured. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting heart rate | 55–70 beats per minute | THC can raise heart rate |
| Blood pressure (seated and standing) | Below 120/80 mmHg seated; standing systolic drop under 20 mmHg | Detects hypertension and orthostatic hypotension |
| ALT and AST | Each 10–26 U/L | THC is cleared by the liver |
| hs-CRP | Below 1.0 mg/L | Tracks systemic inflammation, a proposed cannabinoid target |
| PHQ-9 | 0–4 | Screens depressive symptoms, which THC can worsen |
| GAD-7 | 0–4 | Screens anxiety, a dose-related THC effect |
| CUDIT-R | Below 8 | Screens problematic cannabis use |
| MoCA | 26–30 | Baseline cognition for cognitive-aging goals |
| AHI (only if sleep apnea suspected) | Below 5 events per hour | Measures breathing pauses, the endpoint in the sleep apnea trial |
Cadence: Baseline before starting; 1 week and 4 weeks after starting or changing a dose; then every 3–6 months for heart rate, blood pressure, mood and anxiety scores, and cannabis-use screening; every 6–12 months for liver enzymes, inflammation markers, and cognitive testing